Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group.

Research output: Contribution to journalJournal articleResearch

  1. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. A More COMPLETE Picture of Revascularization in STEMI

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Indirekte tuberkulosediagnostik. Har Mantouxtesten fået en afløser?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Ebola--haemoragisk feber

    Research output: Contribution to journalJournal articleResearchpeer-review

  • C Pedersen
  • E Sandström
  • C S Petersen
  • G Norkrans
  • J Gerstoft
  • A Karlsson
  • K C Christensen
  • C Håkansson
  • P O Pehrson
  • Jens Ole Nielsen
View graph of relations
We performed a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of inosine pranobex (Isoprinosine) [corrected] in the treatment of patients with human immunodeficiency virus (HIV) infection but without manifest acquired immunodeficiency syndrome (AIDS). A total of 866 patients were enrolled in 21 centers in Denmark and Sweden. The patients were stratified in three groups according to their CD4+ cell count and randomly assigned to receive either inosine pranobex (1 g three times a day) (n = 429) or matching placebo (n = 437) for 24 weeks. Of the 831 patients who could be evaluated, AIDS developed in 17 in the placebo group as compared with 2 in the inosine pranobex group (P less than 0.001; odds ratio, 8.6 [95 percent confidence limits, 2.2 and 52.6]). There were no significant differences between the groups with respect to changes in CD4+ cell count or the development of other HIV-related conditions, with the exception of thrush, which developed in fewer patients in the inosine pranobex group (P = 0.05). No serious side effects were observed. We conclude that treatment with inosine pranobex delays progression to AIDS in patients with HIV infection. The duration of this beneficial effect, the optimal dose, and the mode of action of inosine pranobex remain to be clarified.
Translated title of the contributionThe efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group.
Original languageEnglish
JournalNew England Journal of Medicine
Volume322
Issue number25
Pages (from-to)1757-1763
Number of pages7
ISSN0028-4793
Publication statusPublished - 1990

ID: 32506173